Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zimmer

Showing results (301-310 of 384) with videos related to

Pageof 39
Sort By:
Molecular Metabolism|November 17, 2023
Short-term consumption of highly processed diets varying in macronutrient content impair the sense of smell and brain metabolism in miceMelanie Makhlouf, Débora G Souza, Smija Kurian, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 15, 2023
The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging FrameworkArthur C Macedo, Cécile Tissot, Joseph Therriault, et al.
Neuroepidemiology|August 28, 2025
Polypill and RiskOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care (PROMOTE) Randomized Clinical Trial: Rationale and DesignMichael Brainin, Craig S Anderson, Philip M Bath, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 21, 2022
A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's diseaseWagner S Brum, Marco Antônio de Bastiani, Andrei Bieger, et al.
The Journal of Prevention of Alzheimer'S Disease|February 20, 2024
Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's DiseaseA C Macedo, D F P A Durço, C Tissot, et al.
Nature Aging|August 31, 2023
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain casesWagner S Brum, Nicholas C Cullen, Shorena Janelidze, et al.
Ebiomedicine|February 14, 2022
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's diseaseNicholas J Ashton, Andréa L Benedet, Tharick A Pascoal, et al.
Plos Medicine|November 30, 2007
Clinical trials and medical care: defining the therapeutic misconceptionGail E Henderson, Larry R Churchill, Arlene M Davis, et al.
Nature Communications|March 15, 2024
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settingsWagner S Brum, Nicholas C Cullen, Joseph Therriault, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumIlaria Pola, Nicholas J Ashton, Marco Antônio De Bastiani, et al.
Pageof 39

Showing results (301-310 of 384) with videos related to

Sort By:
Pageof 39
Molecular Metabolism|November 17, 2023
Short-term consumption of highly processed diets varying in macronutrient content impair the sense of smell and brain metabolism in miceMelanie Makhlouf, Débora G Souza, Smija Kurian, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 15, 2023
The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging FrameworkArthur C Macedo, Cécile Tissot, Joseph Therriault, et al.
Neuroepidemiology|August 28, 2025
Polypill and RiskOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care (PROMOTE) Randomized Clinical Trial: Rationale and DesignMichael Brainin, Craig S Anderson, Philip M Bath, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 21, 2022
A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's diseaseWagner S Brum, Marco Antônio de Bastiani, Andrei Bieger, et al.
The Journal of Prevention of Alzheimer'S Disease|February 20, 2024
Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's DiseaseA C Macedo, D F P A Durço, C Tissot, et al.
Nature Aging|August 31, 2023
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain casesWagner S Brum, Nicholas C Cullen, Shorena Janelidze, et al.
Ebiomedicine|February 14, 2022
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's diseaseNicholas J Ashton, Andréa L Benedet, Tharick A Pascoal, et al.
Plos Medicine|November 30, 2007
Clinical trials and medical care: defining the therapeutic misconceptionGail E Henderson, Larry R Churchill, Arlene M Davis, et al.
Nature Communications|March 15, 2024
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settingsWagner S Brum, Nicholas C Cullen, Joseph Therriault, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumIlaria Pola, Nicholas J Ashton, Marco Antônio De Bastiani, et al.
Pageof 39